LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Instituto Valenciano de Oncologia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Instituto Valenciano de Oncologia (13)
2023
-
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Nature Communications, Vol. 14, Núm. 1
2022
-
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA
Future Oncology, Vol. 18, Núm. 34, pp. 3791-3800
2014
-
Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists
Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 914-920
2012
-
Recommendations for the optimal management of early and advanced urothelial carcinoma
Cancer Treatment Reviews, Vol. 38, Núm. 5, pp. 431-441
-
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: A phase II study evaluating co-treatment with dexamethasone
Investigational New Drugs, Vol. 30, Núm. 2, pp. 729-740
2010
-
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: Focus on special populations
Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1
-
Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma
Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1
2009
-
Phase II randomized study of plitidepsin (aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma
Marine Drugs, Vol. 7, Núm. 1, pp. 57-70
2007
-
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
Annals of Oncology, Vol. 18, Núm. 3, pp. 522-528
2002
-
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer
British Journal of Cancer, Vol. 86, Núm. 3, pp. 326-330
-
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine
Cancer, Vol. 95, Núm. 4, pp. 751-757
2001
-
Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial
Journal of the National Cancer Institute, Vol. 93, Núm. 1, pp. 31-38
2000
-
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer
European Journal of Cancer, Vol. 36, Núm. SUPPL. 2, pp. 17-25